Correction to: Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries

Affiliations

• ¹ Department of Diabetes, Endocrinology and Metabolism, Royal North Shore Hospital, Sydney, NSW, 2065, Australia. greg.fulcher@sydney.edu.au.
• ² Northern Clinical School, University of Sydney, Sydney, NSW, Australia. greg.fulcher@sydney.edu.au.
• ³ Novo Nordisk Region Asia Pacific, Dubai, United Arab Emirates.
• ⁴ Department of Internal Medicine, Specialized Medical Center Hospital, Riyadh, Saudi Arabia.
• ⁵ Novo Nordisk A/S, Søborg, Denmark.
• ⁶ Department of Medicine, Hospital Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia.
• ⁷ Department of Biochemistry and Molecular Biology, University of the Philippines-College of Medicine, Manila, Philippines.
• ⁸ Department of Endocrinology, Fortis Hospital, Mohali, Punjab, India.
• ⁹ Netcare Union and Clinton Hospitals, Alberton, South Africa.
• ¹⁰ University of the Witwatersrand, Johannesburg, South Africa.